<DOC>
	<DOCNO>NCT00128245</DOCNO>
	<brief_summary>This study evaluate efficacy safety 2 dos pimecrolimus ( 0.3 % 1 % ) ophthalmic suspension moderate severe population keratoconjunctivitis sicca ( KCS , dry eye syndrome ) patient .</brief_summary>
	<brief_title>Safety Efficacy Pimecrolimus Ophthalmic Suspension Patients With Moderate Severe Keratoconjunctivitis Sicca</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>History artificial tear use Moderate severe sign dry eye Moderate severe ocular discomfort Patients uncontrolled systemic ocular disease . Have history refractive surgery Use topical ocular medication dispense study , study Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>KCS</keyword>
	<keyword>dry eye</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>Keratoconjunctivitis sicca ( dry eye syndrome )</keyword>
</DOC>